REGN Factor-Based Stock Analysis

According to Validea's guru fundamental report, REGENERON PHARMACEUTICALS INC (REGN) receives a rating of 86% based on their Benjamin Graham-inspired Value Investor model, indicating the strategy has interest in the stock. The model favors the company's low P/B and P/E ratios, low debt, and solid long-term earnings growth, while the stock fails the model's price/book ratio test. The rating suggests that REGN's fundamentals and valuation align with Graham's deep value investment principles.

Analysis

Regeneron Pharmaceuticals Inc. (REGN) has achieved an 86% rating according to Validea's Value Investor model, which emulates Benjamin Graham's deep value investment strategy, indicating a significant level of interest from this historically successful approach. This high score is attributed to REGN's strong performance on several fundamental metrics, including passing tests for its sector, sales volume, current ratio, low long-term debt in relation to net current assets, robust long-term EPS growth, and a favorable P/E ratio. The analysis highlights that while REGN meets most of Graham's stringent criteria for undervalued stocks with solid financials, it failed the Price/Book ratio test. Despite this, the overall assessment, coupled with a 'strongly positive' sentiment score of 0.65 and a specific ticker sentiment of 0.75 for REGN, suggests a generally favorable outlook based on these fundamental value indicators.

Key Decisions for Investors

• Investors with a value-oriented strategy should consider REGN due to its high rating on the Benjamin Graham model, reflecting strong fundamentals like low P/E and solid long-term EPS growth.
• Further due diligence is warranted on REGN's Price/Book ratio, as its failure to meet this specific Graham criterion is a notable point of divergence in an otherwise positive value assessment.
• Given the overall 86% score and positive sentiment, REGN may present an opportunity for long-term investors, though the specific valuation concern regarding the Price/Book ratio should be carefully evaluated within their risk framework.